EBS

Lobbying Update: $50,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed

$50,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Providing guidance on development, acquisition and stockpiling of medical countermeasures for the US government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA). Funding for medical countermeasure enterprise including, SNS, BARDA and Project BioShield; State Opioid response (SOR) Grant Funding; Substance Abuse and Mental Health Block Grant (SABG) funding. Naloxone access and awareness and opioid prescribing."

You can find more data on corporate lobbying on Quiver Quantitative.

EBS Congressional Stock Trading

Members of Congress have traded $EBS stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $EBS stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

EBS Insider Trading Activity

EBS insiders have traded $EBS stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:

  • DONALD W DEGOLYER sold 25,000 shares.
  • MARVIN L WHITE sold 14,287 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EBS Hedge Fund Activity

We have seen 57 institutional investors add shares of EBS stock to their portfolio, and 83 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.


This article is not financial advice. See Quiver Quantitative's disclaimers for more information.


This article was originally published on Quiver News, read the full story.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.